Turning Point Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was USD 0.46 million compared to USD 25 million a year ago. Net loss was USD 66.33 million compared to USD 17.71 million a year ago. Basic loss per share from continuing operations was USD 1.34 compared to USD 0.42 a year ago. Diluted loss per share from continuing operations was USD 1.34 compared to USD 0.42 a year ago. For the nine months, sales was USD 30.83 million compared to USD 25 million a year ago. Net loss was USD 158.1 million compared to USD 109.92 million a year ago. Basic loss per share from continuing operations was USD 3.21 compared to USD 2.82 a year ago. Diluted loss per share from continuing operations was USD 3.21 compared to USD 2.82 a year ago.